TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04574648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActionADE
Description: ActionADE is a software application that allows healthcare providers to document standardized adverse drug event and non-adherence information in a user-friendly and standardized manner. We integrated ActionADE uni-directionally with PharmaNet, a secure province-wide network that links all pharmacies in British Columbia to a central data system. This allows care providers to pull in demographic information and visualize their patient's medication dispensing history.~In 2020, we enabled bi-directional integration with PharmaNet allowing clinicians to transmit standardized information back to the PharmaNet database. The three dominant community pharmacy systems in the geographic area of the trial will display non-adherence information in their systems.
Study: NCT05885165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised team-based exercise
Description: The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised exercise
Description: The intervention is a 12-week physical exercise program with five training sessions bi-weekly lasting approximately 1 hour each. First two weeks are supervised, the following 10 weeks are unsupervised.
Study: NCT06521983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: Whole body vibration will be applied while standing with a frequency of 30 Hz and an intensity of 2 mm by vibration machine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: Whole body vibration will be applied while standing with a frequency of 30 Hz and an intensity of 2 mm by vibration machine
Study: NCT05480657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AT-1501 IV Infusion
Description: Investigational study drug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isolated cadaveric islet cells
Description: Infusion of human cadaveric islet cells into the portal vein
Study: NCT05017298

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Allogeneic adipose-derived stem cells
Description: Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose-derived stem cells
Description: Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
Study: NCT05940662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Implant Placement
Description: The extraction of the failing tooth will be carried out. Subsequently, immediate implant placement and bone grafting of the intra-alveolar space by the means of a well-documented xenogeneic bone substitute will be carried out, will be conducted all in one single surgical intervention.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Implant Placement
Description: The extraction of the failing tooth will be carried out. Within a healing period of 4-16 weeks, the extraction socket will be completely covered by soft tissues.~Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late Implant Placement
Description: The extraction of the failing tooth and a socket grafting procedure using a well-documented xenogeneic bone substitute will be carried out. Within a healing period of at least 16 weeks, the extraction socket will be completely covered by soft tissues and complete bone healing is anticipated.~Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol).
Study: NCT04461639

Intervention type: DRUG
Intervention: Damoctocog alfa pegol (Jivi, BAY94-9027)
Description: Different prophylaxis regimens with damoctocog alfa pegol following approved local labels or any other regimen prescribed by the physician as part of normal clinical practice
Study: NCT06440395

Intervention type: BEHAVIORAL
Intervention: Behavioural: Small Steps for Big Changes Diabetes Prevention Program
Description: The 4-week behaviour change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 4-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the YMCA). The supervised session will include brief behavioural counselling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.
Study: NCT05558891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: Toward Hope, Recovery, Interpersonal Relationships, Values and Engagement (THRIVE), is a brief, suicide-specific, narrative, recovery-focused, 60 minute intervention. THRIVE includes three components: 1) Sharing the suicide narrative; 2) Completing the Lifeline and Meaning Reconstruction; 3) Completing the Meaningful Living Plan (MLP).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Care as Usual in this Crisis Stabilization Unit includes medication management, medication management, safety planning Intervention, group psychoeducation, discharge planning, and community linkages

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Care as Usual in this Crisis Stabilization Unit includes medication management, medication management, safety planning Intervention, group psychoeducation, discharge planning, and community linkages
Study: NCT04734145

Intervention type: DIAGNOSTIC_TEST
Intervention: Breathprinting test
Description: Consented, enrolled participants will undergo a breathprinting test (e-nose) during the presurgical visit and at the same facility as their presurgical or prebiopsy visit, before any attempt is made to obtain cytohistological diagnosis of the pulmonary nodule.
Study: NCT05328804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag
Description: Orally by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag
Description: Orally by mouth
Study: NCT06381609

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality life questionnaire AQoLS
Description: Quality life questionnaire AQoLS will be completed by patients of both arms at inclusion, three and six months after inclusion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality life questionnaire AQoLS
Description: Quality life questionnaire AQoLS will be completed by patients of both arms at inclusion, three and six months after inclusion

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality life questionnaire Euroqol EQ-5D-5L
Description: Quality life questionnaire Euroqol EQ-5D-5L will be completed by patients of both arms at inclusion, three and six months after inclusion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality life questionnaire Euroqol EQ-5D-5L
Description: Quality life questionnaire Euroqol EQ-5D-5L will be completed by patients of both arms at inclusion, three and six months after inclusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer support consultations
Description: For patients included in the Peer support group, eight mandatory consultations with a peer support specialist will be performed between the inclusion visit and during the three following months.~Patients can request additional consultations with the peer support specialist during the 6 first months of follow-up
Study: NCT05367388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101
Description: APL-101 (Vebreltinib) is an orally available small molecule, which is a tyrosine kinase inhibitor (TKI) for the mesenchymal epithelial transition protein tyrosine kinase receptor (c-Met) with high selectivity and potency.~The treatments to be administered in this study include:~• Treatment A (reference): Two 100 mg APL-101 (Vebreltinib) capsules (200 mg dose), manufactured for Apollomics, Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-101
Description: APL-101 (Vebreltinib) is an orally available small molecule, which is a tyrosine kinase inhibitor (TKI) for the mesenchymal epithelial transition protein tyrosine kinase receptor (c-Met) with high selectivity and potency.~The treatments to be administered in this study include:~• Treatment A (reference): Two 100 mg APL-101 (Vebreltinib) capsules (200 mg dose), manufactured for Apollomics, Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLB-1001
Description: PLB-1001 (Bozitinib) is a chemical drug category 1.1 innovative drug. It is a highly effective and highly selective c-Met tyrosine kinase inhibitor.~The treatments to be administered in this study include:~• Treatment P (test): Two 100 mg PLB-1001 (Bozitinib) capsules (200 mg dose), manufactured for Beijing Pearl Biotechnology Co., Ltd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLB-1001
Description: PLB-1001 (Bozitinib) is a chemical drug category 1.1 innovative drug. It is a highly effective and highly selective c-Met tyrosine kinase inhibitor.~The treatments to be administered in this study include:~• Treatment P (test): Two 100 mg PLB-1001 (Bozitinib) capsules (200 mg dose), manufactured for Beijing Pearl Biotechnology Co., Ltd.
Study: NCT05124574

Intervention type: OTHER
Intervention: Samples concern SARS-COV-2 + pregnant women at the time of childbirth
Description: * nasopharyngeal PCR in the mother (performed systematically in this epidemic context),~* Blood samples: 1 EthyleneDiamineTetraacetic Acid (EDTA) tube (immunohistochemistry), 1 yellow tube (COVID + RT-qPCR serology).~* Sampling of amniotic fluid in case of cesarean section~* Sampling of the placenta for histological and virological study.

Intervention type: OTHER
Intervention: Samples concern newborns of SARS-COV-2 + mothers at birth
Description: * In the birth room:~  * Collection of gastric fluid (PCR SARS-COV-2),~ * Cord blood: 1 EDTA tube (immunohistochemistry), 1 yellow tube (SARS-COV-2 + RT-qPCR serology).~* In the newborn at D3 of life:~  - 1 yellow tube (SARS-COV-2 + RT-qPCR serology) at the same time as the DNN.~* In symptomatic newborns:~  * 1 yellow tube (SARS-COV-2 + RT-qPCR serology).~ * nasopharyngeal PCR,
Study: NCT04730505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyHOPE™ for Multiple Myeloma
Description: The MyHOPE for MM Platform is designed to provide patients with tools and resources to support them in their overall experience with MM. Patients can share their data through a PDF or by showing their device to their care team at clinic visits.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyHOPE™ for Multiple Myeloma
Description: The MyHOPE for MM Platform is designed to provide patients with tools and resources to support them in their overall experience with MM. Patients can share their data through a PDF or by showing their device to their care team at clinic visits.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyHope HCP Portal
Description: Is designed to provide HCPs with the ability to view patient data and symptom notifications (Cohort 1 only) to provide support between clinic visits and to facilitate dialogue during clinic visits.
Study: NCT05378126

Intervention type: OTHER
Group type: OTHER
Intervention: Neurological assessment
Description: No specific procedure is planned for the study other than the neurological examination by a neurologist of all patients. The patient will be taken care according to current recommendations.~In addition, a study-specific, non-injected brain CT scan will be performed systematically in patients undergoing cardiac surgery to evaluate postoperative hemorrhagic transformation.
Study: NCT05189405

Intervention type: DEVICE
Intervention: INVOcell IVC
Description: Embryo development in intravaginal incubation
Study: NCT05942703

Intervention type: OTHER
Intervention: saliva samples
Description: Saliva samples, which are part of the usual treatment, will be carried out before and after the non-surgical periodontal treatment

Intervention type: OTHER
Intervention: saliva samples
Description: Saliva samples, which are part of the usual treatment, will be carried out before and after the non-surgical periodontal treatment
Study: NCT06247657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL0006
Description: Patients will be administered BL0006 via intravenous infusion at the corresponding dose level on days 1 and 8 of a 21-days treatment cycle.
Study: NCT05536518

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mid-Ohio Farmacy (produce prescription) + WW International Coaching (In person and/or Virtual)
Description: All study participants are members of the Mid-Ohio Farmacy produce prescription program. All participants are food insecure and will be enrolled and participate in WW coaching sessions for 24 weeks.
Study: NCT04096703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumatic dilation
Description: The patients randomized to the pneumatic dilation cohort will undergo an initial pneumatic dilation with a 30mm Rigiflex (Boston Scientific). If the Eckardt score four weeks after initial dilation is \> 4, then the patient will be scheduled for a second dilation with a 35mm Rigiflex balloon (Boston Scientific).
Study: NCT05527678

Intervention type: OTHER
Intervention: Questionnaires
Description: Written or by phone
Study: NCT05283005

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Grafting of the alveolar cleft
Description: alveolar cleft grafting using either the conventional technique or the double cortex technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Grafting of the alveolar cleft
Description: alveolar cleft grafting using either the conventional technique or the double cortex technique
Study: NCT04916938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interaction Guidance Therapy
Description: Mother child psychotherapy based on video-feedback interaction after a free play session. The therapy usually enhances parent sensibility to the child.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mother's child psychotherapeutic session
Description: Mother's representation of the event, mother's representation of the relation to her child, maternal emotions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interview
Description: History and perception of the mother's issues.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: History and perception of the mother's issues.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-rated questionnaires
Description: Parental Self-Questionnaire to assess the perception of the evolution of the father, mother and child

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-rated questionnaires
Description: Parental Self-Questionnaire to assess the perception of the evolution of the father, mother and child
Study: NCT05141097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative medicine approach
Description: By treated by integrative medicine approaches instead of conventional medicine
Study: NCT05251025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive sustained stretching
Description: The Group A received Passive Stretching Technique. Along with the Passive Stretching Technique, this group also received certain conventional treatments which included resistive exercises, gait training exercises, bridging and exercises in other functional positions were also undertaken by the included individuals.~All the exercises mentioned above were performed for 30 minutes and there was not any specific division of time for all these mentioned activities. The patients used to perform these conventional treatments and exercises on their motor control basis. The exercises were performed for 30 minutes and been done for 5 days in a week for consecutive 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release
Description: The Group B received Myofascial Release Technique and along with conventional treatments. The Myofascial Release Technique for hamstrings was given to the patient in prone position. The technique was applied either by the crossed hands or thumbs. This total treatment was given for 30 minutes consecutively. After the technique the Myofascial structures were stretched and then were hold for straight 120 seconds so that the tissues get softened. The technique was given to patients with 6 repetitions and with a hold for 120 seconds. The treatment was continued for 5 days a week for straight 6 weeks.
Study: NCT06078878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HF-OCT Imaging System with Vis-M Micro-Imaging Catheter
Description: Subjects undergo HF-OCT imaging of the desired intravascular segement
Study: NCT06327607

Intervention type: OTHER
Intervention: Control Group
Description: Standard care for breast cancer

Intervention type: OTHER
Intervention: Psychosexological intervention
Description: The intervention will be conducted individually and will take place once a week for one hour, for a total of 8 consecutive weeks, which must be completed within a maximum duration of 10 weeks.
Study: NCT06051240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium sulphate, 42 mg (6 mmol lithium)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White round tablet, 10 mm. Identical to experimental drug (lithium)
Study: NCT06035445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person adolescent-friendly service (iPAS) intervention
Description: Monthly visits take place in a group setting with sessions led by peer educators. Clinical staff and peer educators are trained in care of adolescents using the Right to Care training materials. During their clinic visit, adolescents are evaluated individually by a healthcare provider and receive their supply of ART. In addition, adolescents participate in scheduled group team-building activities including dancing, sports, music and receive group counseling facilitated by peer educators. Nine group counseling sessions will discuss the topics of: HIV disclosure, alcohol and substance abuse, HIV knowledge, ART adherence and HIV resistance, goal setting and career planning, sexual and reproductive health, HIV stigma, healthcare navigation and self-advocacy, and healthy relationships. The half-day sessions will end with the provision of a meal. After completion of the 9-month intervention, adolescents will transition to adult care in their standard local adult clinic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth (InTSHA) intervention
Description: The InTSHA intervention is based on Got Transition elements (two-way messaging between adolescents and healthcare providers) and the SMART model. The SMART model focuses on modifiable factors of transition preparation through content delivery, facilitated discussions, online meet ups and consultation with the healthcare team. The intervention consists of 9 modules delivered monthly by group chat. The topics of the modules are: HIV disclosure, alcohol and substance abuse, HIV knowledge, ART adherence and HIV resistance, goal setting and career planning, sexual and reproductive health, HIV stigma, healthcare navigation and self-advocacy, and healthy relationships. Outside of scheduled group chat sessions, adolescents have access to the chat group to check in with members, review content of the sessions, or to comment or ask additional questions. After completion of the 9-month intervention, adolescents will transition to adult care in their standard local adult clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Adolescents in standard of care are seen every three months by clinicians and collect medication monthly at an on-site pharmacy during regular weekdays. Individual counseling delivered by counselors or social workers is available when necessary. Staff at all clinics receive training in adolescent-friendly services (AFS) through the Right to Care training materials.
Study: NCT05325047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive speech rehabilitation
Description: Combination an e-health device allowing the patient to self-rehabilitate with a face-to-face approach of accompaniment and support of the patient by the speech therapist.
Study: NCT05247658

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic lens alone
Description: Therapeutic lens will be apposed on patient's dominant eye after bilateral PRK. Therapeutic lens will be maintained without interruption until the first postoperative visit when it will be removed by the surgeon.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic lens + amniotic membrane (Visio-AMTRIX)
Description: Amniotic membrane (Visio-AMTRIX) will be apposed under therapeutic lens on patient's non-dominant eye after bilateral PRK. Amniotic membrane and therapeutic lens will be maintained without interruption until the first postoperative visit when it will be removed by the surgeon.
Study: NCT05357755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally as delayed release tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally as delayed release tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally as delayed release tablets.